30 September 2021: Clinical Research
Prospective Study on the Postoperative Use of Levosimendan After Conventional Heart Valve Replacement
Wei Sheng ABCDEF* , Hui Qiao ABCDEF* , Zhaozhuo Niu BCE , Tianyi Wang BCE , Haoyou Li CDE , Wenfeng Zhang CDE , Jiantao Wu CDE , Xiao Lv ADEF*DOI: 10.12659/MSM.932001
Med Sci Monit 2021; 27:e932001
Table 3 Comparison of other perioperative parameters between the 2 groups.
| Parameter | Levosimendan (n=93) | Control (n=92) | χ2 or t value | P value |
|---|---|---|---|---|
| Average dosage of dopamine after surgery (mg/Kg, mean±SD) | 11.5±1.8 | 20.4±2.1 | 30.960 | 0.000 |
| Administration time of dopamine after surgery (h, mean±SD) | 70.4±11.2 | 110.5±12.1 | 23.396 | 0.000 |
| Duration of mechanical ventilation (h, mean±SD) | 13.5±3.6 | 14.2±4.2 | 1.218 | 0.225 |
| ICU length of stay (h, mean±SD) | 24.6±4.3 | 32.5±4.6 | 12.068 | 0.000 |
| Perioperative adverse events | 9 | 25 | 9.438 | 0.002 |
| Low cardiac output | 0 | 5 | 5.195 | 0.023 |
| Renal insufficiency | 1 | 7 | 4.772 | 0.029 |
| Perioperative myocardial infarction | 0 | 0 | 5.283 | 0.022 |
| New atrial fibrillation | 6 | 16 | 0.350 | 0.554 |
| Malignant arrhythmia | 0 | 0 | ||
| Re-exploration | 1 | 2 | ||
| ICU – Intensive Care Unit. | ||||